Tourmaline Bio Competitors and Similar CompaniesClear all

Tourmaline Bio's competitors and similar companies include Inotiv, FIS, Alfasigma and Guizhou Sanli Pharmaceutical.

	Tourmaline Bio Tourmaline Bio is a late-stage clinical biotechnology company that develops medicines for life-altering immune and inflammatory diseases.	Inotiv Inotiv (formerly known as BioAnalytical Systems) is a company that provides research services to pharmaceutical and biotechnology companies.	FIS FIS (Fabbrica Italiana Sintetici) is a developer and producer of active pharmaceutical ingredients.	Alfasigma Alfasigma is a pharmaceutical company providing prescription and over-the-counter drugs.	Guizhou Sanli Pharmaceutical Guizhou Sanli Pharmaceutical (贵州三力制药股份有限公) researches and develops medicinal products.
Founding Date	Founding Date 2002	Founding Date 1974	Founding Date 1957	Founding Date 2015	Founding Date 1995
Type	Type Public	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare clinical research drug development drug monitoring pharma	Tags Healthcare biotech clinical research drug development drug monitoring life sciences pharma	Tags Healthcare clinical research drug development drug monitoring pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma
Locations	Locations New York, US HQ	Locations West Lafayette, US HQ	Locations Montecchio Maggiore-Alte Ceccato, IT HQ Termoli, IT Vicenza, IT	Locations Bologna, IT HQ Bruxelles, BE Issy Les Moulineaux, FR Mumbai, IN see more	Locations An Shun Shi, CN HQ
Employees	Employees N/A	Employees 1,945	Employees 1,2231% increase	Employees 2,5061% increase	Employees 2,85225% increase
Valuation ($)	Valuation ($) 694.9 m	Valuation ($) 47.3 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 796.5 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $513m (FY, 2025)	Revenue (est.) €562.1m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) ¥2.1b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods $392m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥650m (FY, 2024)
Gross profit	Gross profit N/A	Gross profit $121m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit ¥1.5b (FY, 2024)
Net income	Net income ($73.2m) (FY, 2024)	Net income ($68.6m) (FY, 2025)	Net income N/A	Net income N/A	Net income ¥279.8m (FY, 2024)